Business Context and Reporting Period
This Form 8-K is a Current Report filed by Lantheus Holdings, Inc. (LNTH) on September 17, 2026. The filing addresses Item 8.01 (Other Events) regarding the ongoing regulatory review of the Company's proposed acquisition by Curium US Holdings LLC ("Parent").
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the status of the merger transaction and regulatory proceedings.
Material Changes and Transaction Status
- HSR Withdrawal and Refiling: On September 17, 2026, Parent voluntarily withdrew its pre-merger Notification and Report Form filed under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) to provide the Federal Trade Commission (FTC) additional time for review.
- New Waiting Period: Parent resubmitted the notification on September 21, 2026, initiating a new 30-day waiting period scheduled to expire on October 21, 2026, unless extended by the FTC.
- Transaction Structure: The Merger Agreement, originally entered into on August 3, 2026, provides for Merger Sub to merge with and into Lantheus, with Lantheus surviving as a wholly owned subsidiary of Parent.
Guidance, Outlook, and Risks
Outlook: Management continues to expect to consummate the Merger in the first half of 2027, subject to regulatory approvals, stockholder adoption, and satisfaction of other closing conditions.
Key Risks and Contingencies:
- Regulatory Approval: The transaction is contingent on the expiration or termination of the HSR waiting period and receipt of other required regulatory approvals.
- Stockholder Approval: The Merger Agreement must be adopted by the Company's stockholders.
- Operational Disruption: Risks include diversion of management attention, potential disruption to business operations, and impacts on suppliers and partners.
- Product-Specific Risks: The filing highlights risks related to the commercialization and manufacturing of key products, including PYLARIFY TruVu (approved March 6, 2026) and TAUKLARIFY (approved August 14, 2026), as well as the achievement of milestones for Contingent Value Rights (CVRs).
- Leadership Changes: The filing notes recent turnover in the Company's leadership and senior management team as a potential risk factor.
Investor Verification Checklist
- Review the definitive proxy statement filed with the SEC on September 8, 2026, for detailed terms of the acquisition.
- Monitor the status of the FTC's review and the expiration of the HSR waiting period on October 21, 2026.
- Verify the timeline for stockholder voting on the Merger Agreement.
- Assess the progress of FDA approvals and manufacturing technology transfers for PYLARIFY TruVu and TAUKLARIFY.
- Review Form 3 and Form 4 filings for changes in beneficial ownership by directors and executive officers.